Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Other Non-Current Assets (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Other Non-Current Assets for 12 consecutive years, with $148000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets rose 111.43% year-over-year to $148000.0, compared with a TTM value of $148000.0 through Sep 2025, up 111.43%, and an annual FY2024 reading of $92000.0, down 43.9% over the prior year.
  • Other Non-Current Assets was $148000.0 for Q3 2025 at Arcadia Biosciences, up from $96000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $182000.0 in Q3 2021 and bottomed at $23000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $137235.3, with a median of $164000.0 recorded in 2023.
  • Peak annual rise in Other Non-Current Assets hit 665.22% in 2021, while the deepest fall reached 91.0% in 2021.
  • Year by year, Other Non-Current Assets stood at $180000.0 in 2021, then tumbled by 86.67% to $24000.0 in 2022, then soared by 583.33% to $164000.0 in 2023, then tumbled by 43.9% to $92000.0 in 2024, then soared by 60.87% to $148000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for RKDA at $148000.0 in Q3 2025, $96000.0 in Q1 2025, and $92000.0 in Q4 2024.